Key Takeaways in the Treatment of Advanced RCC From KCRS 2023
Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.
EP: 1.Overview of First-Line Combination Therapy in Advanced Clear Cell RCC
EP: 2.Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC
EP: 3.Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
EP: 4.Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC
EP: 5.Selecting Therapy for a Real-World Patient With Clear Cell RCC
EP: 6.Rationale Behind Discontinuing IO Therapy in Clear Cell RCC
EP: 7.Second-Line Treatment Armamentarium in Clear Cell RCC
EP: 8.Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies
EP: 9.Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
EP: 10.Renal Cell Carcinoma: Future Evolutions in Care
EP: 11.Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)
EP: 12.Available Treatment Options for Patients with Advanced RCC
EP: 13.Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC
EP: 14.Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC
EP: 15.Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC
Now Viewing
EP: 16.Key Takeaways in the Treatment of Advanced RCC From KCRS 2023
EP: 17.Future Perspectives in the Treatment of Advanced RCC
Related Videos
